76 related articles for article (PubMed ID: 9546797)
1. Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion.
Silburn KA; McPhee DA; Maerz AL; Poumbourios P; Whittaker RG; Kirkpatrick A; Reilly WG; Manthey MK; Curtain CC
AIDS Res Hum Retroviruses; 1998 Mar; 14(5):385-92. PubMed ID: 9546797
[TBL] [Abstract][Full Text] [Related]
2. Membrane-perturbing domains of HIV type 1 glycoprotein 41.
Mobley PW; Pilpa R; Brown C; Waring AJ; Gordon LM
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):311-27. PubMed ID: 11242518
[TBL] [Abstract][Full Text] [Related]
3. The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.
Huang JH; Yang HW; Liu S; Li J; Jiang S; Chen YH
Biochem J; 2007 May; 403(3):565-71. PubMed ID: 17223796
[TBL] [Abstract][Full Text] [Related]
4. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
Pritsker M; Rucker J; Hoffman TL; Doms RW; Shai Y
Biochemistry; 1999 Aug; 38(35):11359-71. PubMed ID: 10471286
[TBL] [Abstract][Full Text] [Related]
5. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
Dimitrov AS; Rawat SS; Jiang S; Blumenthal R
Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682
[TBL] [Abstract][Full Text] [Related]
6. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.
Jin BS; Ryu JR; Ahn K; Yu YG
AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1797-804. PubMed ID: 11118065
[TBL] [Abstract][Full Text] [Related]
7. Oligopeptide inhibitors of HIV-induced syncytium formation.
Owens RJ; Tanner CC; Mulligan MJ; Srinivas RV; Compans RW
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1289-96. PubMed ID: 2078410
[TBL] [Abstract][Full Text] [Related]
8. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
9. Membrane perturbing actions of HIV type 1 glycoprotein 41 domains are inhibited by helical C-peptides.
Mobley PW; Barry JA; Waring AJ; Sherman MA; Gordon LM
AIDS Res Hum Retroviruses; 2007 Feb; 23(2):224-42. PubMed ID: 17331029
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of a hydrophobic tripeptide on human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and viral infectivity.
Konopka K; Pretzer E; Düzgünes N
Biochem Biophys Res Commun; 1995 Mar; 208(1):75-81. PubMed ID: 7887968
[TBL] [Abstract][Full Text] [Related]
11. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.
Sánchez-Martín MJ; Urbán P; Pujol M; Haro I; Alsina MA; Busquets MA
Chemphyschem; 2011 Oct; 12(15):2816-22. PubMed ID: 21905195
[TBL] [Abstract][Full Text] [Related]
12. Ability of antibodies specific to the HIV-1 envelope glycoprotein to block the fusion inhibitor T20 in a cell-cell fusion assay.
Vincent N; Malvoisin E
Immunobiology; 2012 Oct; 217(10):943-50. PubMed ID: 22387075
[TBL] [Abstract][Full Text] [Related]
13. The hydrophobic internal region of bovine prion protein shares structural and functional properties with HIV type 1 fusion peptide.
Sáez-Cirión A; Nieva JL; Gallaher WR
AIDS Res Hum Retroviruses; 2003 Nov; 19(11):969-78. PubMed ID: 14678604
[TBL] [Abstract][Full Text] [Related]
14. Mutations of conserved glycine residues within the membrane-spanning domain of human immunodeficiency virus type 1 gp41 can inhibit membrane fusion and incorporation of Env onto virions.
Miyauchi K; Curran R; Matthews E; Komano J; Hoshino T; Engelman DM; Matsuda Z
Jpn J Infect Dis; 2006 Apr; 59(2):77-84. PubMed ID: 16632906
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
16. Natural variation in the amino acid sequence around the HIV type 1 glycoprotein 160 cleavage site and its effect on cleavability, subunit association, and membrane fusion.
Adams O; Schaal H; Scheid A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1235-45. PubMed ID: 10957721
[TBL] [Abstract][Full Text] [Related]
17. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
[TBL] [Abstract][Full Text] [Related]
18. Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors.
Li J; Chen X; Huang J; Jiang S; Chen YH
Immunobiology; 2009; 214(1):51-60. PubMed ID: 19159827
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues.
Delahunty MD; Rhee I; Freed EO; Bonifacino JS
Virology; 1996 Apr; 218(1):94-102. PubMed ID: 8615045
[TBL] [Abstract][Full Text] [Related]
20. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
